Beta-blocker-associated hypoglycaemia: New insights from a real-world pharmacovigilance study.

Nadolol appears to be the β-blocker significantly most associated with hypoglycaemia and children represent the most susceptible sample. Furthermore, long half-life and nonselective β-blockers seem to increase the risk for its occurrence.